The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute of Medicinal Chemistry (SRIMC) in Hungary plays in the group’s overall R&D activities. He also elaborates on the crucial importance of maintaining open communication channels between the three primary stakeholders encompassing the patients—government, doctors, and pharma companies—when introducing new innovations into the healthcare system.
What items have been at the top of your agenda since taking over the helm of Servier Hungary in October 2015?
When it comes to Eastern European markets, the central issue always comes back to price when working with innovative products.
